As Xarelto Lawsuits Mount in U.S., Health Canada Announces Safety Review, Bernstein Liebhard LLP Reports

September 8, 2015 - As Xarelto bleeding lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that regulators in Canada recently announced that they were investigating reports of liver injuries potentially associated with the new-generation blood thinner. According to a Health Canada notification issued on August 26th, the country's Vigilance Program has received 61 reports of liver injuries in patients taking Xarelto, while World Health Organization's (WHO) database showed 431 cases of liver injury. In 23 of those cases, Xarelto was the only drug used in 23 of the incidents noted in the WHO database.

Health Canada has been unable to establish a clear link between the reported liver injuries and the use of Xarelto. For the time being, the regulator is encouraging the reporting of liver-related harmful effects that may be linked to the use of Xarelto, and will continue to monitor the drug to identify and assess potential harms. Health Canada also noted that Xarelto's Canadian prescribing information explains that the medication should not be taken by people who have liver disease linked to problems with blood clotting, and have a risk of bleeding.

"Our Firm is currently representing individuals in the U.S. who allegedly experienced serious internal bleeding and other complications while using Xarelto. As such, we are monitoring any issues related to its safety with great interest," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.

Xarelto Litigation
Xarelto was initially approved by the U.S. Food & Drug Administration in 2011, and is now indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any blood thinner, Xarelto can sometimes cause episodes of serious internal bleeding. However, there is currently no approved antidote to reverse the drug's anticoagulant effects. Xarelto's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.

Court documents indicate that more than 1,600 Xarelto lawsuits have been filed in U.S. courts on behalf of patients who allegedly experienced uncontrollable internal bleeding and other complications related to its use. These cases include more than 1,200 that are pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana.( (In Re: Xarelto Products Liability Litigation, No. 2592) At least 382 claims have been filed in a mass tort litigation moving forward in Pennsylvania's Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)

All of these complaints accuse Xarelto's manufacturers of failing to warn patients about its potential risks, and assert that the drug's sales were driven by marketing claims that positioned the medication as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, lawsuits point out that internal hemorrhaging associated with warfarin can be stopped via the administration of vitamin K.

Xarelto patients who experienced life-threatening episodes of internal bleeding and other complications allegedly related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or by calling 800-511-5092 to schedule a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author